IRVINE, Calif., Aug. 09, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June 30, 2022. “The second quarter was a very productive period for the company, highlighted by advancements… Continue reading Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results
